Priming MSCs for user-friendly action: an interview with Lindsay Davies

In this interview, Lindsay Davies, Chief Scientific Officer at NextCell Pharma (Stockholm, Sweden), discusses the development of mesenchymal stromal/stem cell (MSC)-based therapies for autoimmune and inflammatory diseases. Lindsay highlights the pivotal moment in bringing a pooled MSC-based cell therapy product to clinic, the key considerations for creating user-friendly MSC products, and strategies for leveraging the mechanisms of MSCs, which are quite often challenging to harness for advanced therapies. Would you mind introducing yourself and telling us a bit about NextCell Pharma? My name is Lindsay Davies and I’m the Chief Scientific Officer at NextCell Pharma. I am a cell biologist...